Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

@article{Harries2004PhaseIS,
  title={Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours},
  author={Mark Harries and Anne O'Donnell and Michelle Scurr and Sarah Reade and Catherine Cole and Ian Judson and Alastair Peter Greystoke and Christopher J. Twelves and Stanley B. Kaye},
  journal={British Journal of Cancer},
  year={2004},
  volume={91},
  pages={1651 - 1655}
}
DHA–paclitaxel is a conjugate of paclitaxel and the fatty acid, docosahexaenoic acid. Preclinical studies have demonstrated increased activity, relative to paclitaxel, with the potential for an improved therapeutic ratio. We conducted a phase I study to determine the maximum tolerated doses of DHA–paclitaxel and carboplatin when administered in combination… CONTINUE READING